Quantcast

Latest Lipodystrophy Stories

2014-05-29 04:21:56

AHMEDABAD, India, May 29, 2014 /PRNewswire/ -- Commences Phase III trials of Lipaglyn(TM) (Saroglitazar) in patients suffering from Lipodystrophy Exploring newer therapeutic usage of its breakthrough drug Lipaglyn(TM) (Saroglitazar), the Zydus Group has now initiated Phase III trials of the molecule for patients suffering from lipodystrophy. The drug is already approved in India for treating diabetic dyslipidemia and hypertriglyceridemia. The goal of this trial is to...

2014-03-04 23:31:31

Patients, Researchers, Industry and Leading Medical Experts Join Forces to Gain Patient Population Information San Mateo, CA (PRWEB) March 04, 2014 PatientCrossroads, Lipodystrophy United and international disease experts have launched the Lipodystrophy Connect (LD Connect) patient registry program to learn more about lipodystrophy by collecting information directly from patients. The data will be made broadly available to researchers to speed the search for treatments and to raise the...

2011-06-04 10:45:00

SAN DIEGO, June 4, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced results from a study that showed treatment with metreleptin, an investigational treatment that is an analog of the human hormone leptin, improved diabetes and lipid control in patients with partial lipodystrophy. Data from this study, the first findings from patients receiving metreleptin through Amylin's lipodystrophy expanded access program, were presented at the 93rd Annual Meeting and...

2010-12-20 07:00:00

SAN DIEGO, Dec. 20, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that it has submitted the initial sections of a rolling submission for a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the use of metreleptin to treat diabetes and/or hypertriglyceridemia (high levels of triglycerides in the bloodstream) in patients with rare forms of lipodystrophy. Consistent with the severity and rare nature of the...

2010-11-11 06:35:00

ROCKLAND, Mass., Nov. 11, 2010 /PRNewswire/ -- EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced that the U.S. Food and Drug Administration (FDA) has approved EGRIFTA(TM) (tesamorelin for injection) as the first and only treatment indicated to reduce excess abdominal fat in HIV-infected patients with lipodystrophy (abdominal lipohypertrophy). EGRIFTA(TM) (tesamorelin for injection), developed by Theratechnologies, a Canadian biopharmaceutical company, will...

2010-11-10 18:00:00

SILVER SPRING, Md., Nov. 10 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Egrifta (tesamorelin) to treat HIV patients with lipodystrophy, a condition in which excess fat develops in different areas of the body, most notably around the liver, stomach, and other abdominal organs. The condition is associated with many antiretroviral drugs used to treat HIV. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) (Logo:...

2008-11-06 15:00:28

Theratechnologies (TSX: TH) announced today that new 26-week data from a combined analysis of both its Phase 3 clinical trials testing tesamorelin in HIV-associated lipodystrophy were presented as a poster (Poster Number 19) at the 10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, in London, England. The results of the combined Phase 3 trials presented at this HIV-focused workshop indicate that a daily administration of 2 mg of tesamorelin is beneficial in...

2008-08-04 12:01:30

Theratechnologies (TSX: TH) today announced positive data related to body image for patients treated with tesamorelin in both its first and confirmatory Phase 3 clinical trials, in two poster presentations at the XVII International AIDS Conference in Mexico City, Mexico. Body image parameters are considered an important secondary endpoint and a clinical benefit of both Phase 3 studies. The Company will also sponsor a symposium entitled "Body Fat Changes and Metabolic Complications in the...


Word of the Day
out-herod
  • In the phrase to out-herod Herod, to be more violent than Herod (as represented in the old mystery plays); hence, to exceed in any excess of evil.
Herod refers to 'Herod the Great,' a Roman client king and 'a madman who murdered his own family and a great many rabbis.' According to the OED, the term is 'chiefly with allusion to Shakespeare's use' in Hamlet.
Related